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Pulmonary calcification in hemodialysis patients: Correlation
with pulmonary artery pressure values.
Background. End-stage renal disease (ESRD) patients re-
ceiving chronic hemodialysis (HD) via an arteriovenous (A-
V) access often develop unexplained pulmonary hypertension
(PHT). This study evaluated the role of pulmonary calcification
(PC) in this phenomenon.
Methods. The clinical manifestations, systolic pulmonary
artery pressure (PAP) values measured by Doppler echocar-
diography and the presence and the extent of PC expressed by
lung uptake of 99mTc-MDP bone scintigraphy, were studied in
49 patients with ESRD receiving chronic HD therapy via A-V
access. The correlation between PC and PHT was investigated.
Results. There were 36 men and 13 women with a mean age of
61.7 ± 13.2 years receiving HD therapy for 38.2 ± 43.7 months.
Twenty (40.8%) patients had PC expressed by increased lung
uptake of 99mTc- MDP and 28 (57.1%) patients had PHT with a
mean systolic PAP of 46 ± 11 mm Hg. No correlation was found
between PC and PHT.
Conclusion. The data suggest that PC expressed by lung up-
take of 99mTc-MDP has no role in the pathogenesis of PHT
among ESRD patients undergoing HD therapy via A-V access.
Extraosseous pulmonary calcification (PC) is found
most commonly in end-stage renal disease (ESRD) pa-
tients on chronic hemodialysis (HD) therapy [1–3]. Calci-
fications can occur in any tissue of the body but are found
most commonly in the heart, lungs, kidney, and stomach.
In the lungs, calcium deposits have been found in the in-
terstitium of the alveolar septum, bronchiole walls, in the
large airways, and even in the walls of the pulmonary ves-
sels [4–6]. The clinical manifestations of PC are usually
minimal. Occasionally, PC may cause profound respira-
tory disturbances [1, 2].
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In a recently published study [7], we evaluated the in-
cidence of pulmonary hypertension (PHT) in ESRD pa-
tients using Doppler echocardiography. Almost 40% of
HD patients had systolic PAP above 35 mm Hg, and their
cardiac-output (CO) was significantly higher compared
with HD patients without PHT. Because the study pop-
ulation had no obvious cause for PHT, we assumed that
both ESRD and HD therapy via arteriovenous (A-V)
access might be involved in the pathogenesis of this syn-
drome. Increased CO per se does not cause PHT unless
the capacity of the pulmonary circulation is diminished.
Pulmonary calcification in the vascular compartment of
HD patients is a possible explanation.
X-ray film and computerized tomography (CT) of the
chest, high resolution computed tomography scan with
mediastinal images, technetium 99m–labeled [99mTc]–
MDP bone scanning, and magnetic resonance imaging
(MRI) have all shown variable diagnostic values in de-
tecting PC [8–15]. 99mTc-MDP bone scintigraphy is con-
sidered to be a sensitive measure of PC in ESRD, and, in
addition, enables semiquantitative evaluation of the PC
[11].
This study evaluated the extent of pulmonary uptake of
99mTc-MDP bone scintigraphy in a group of HD patients
and correlated this uptake to the occurrence of PHT.
METHODS
Patients
Our local institutional clinical research ethics review
board approved the research protocol. All participants
signed an informed consent before entering the study.
Patient selection
A total cohort of 110 ambulatory patients with ESRD
receiving chronic HD therapy via a surgically created A-
V access in our institution was reviewed. Patients with
known cardiac (N = 37), pulmonary (N = 6), and sys-
temic diseases (N = 4) were excluded from the study. An
additional 14 patients refused to participate in the study.
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Fig. 1. Study flowchart.
The remaining 49 patients comprised the study popula-
tion (Fig. 1).
The study group underwent evaluation that included
physical examination, chest radiography, and blood tests
for calcium, phosphorus, and parathyroid hormone level.
Age, sex, comorbidity, medications used, etiology of kid-
ney disease, age at onset, and duration of HD therapy
were recorded from patient files.
Hemodialysis patients with systolic PAP above 35 mm
Hg underwent further evaluation by a specialist pul-
monologist that included computed tomography of the
chest, complete pulmonary function tests, measurement
of blood gases and O2 saturation while breathing room
air, and ventilatory perfusion radioisotope lung scan in-
tended to disclose other causes of PHT. None of the pa-
tients was excluded from the study after this work-up.
Echocardiography
To avoid overestimation of PAP due to volume over-
load, all the Doppler measurements were performed
within one hour after completion of dialysis. One experi-
enced operator, masked with regard to the clinical status
of the patient, performed all echocardiography studies
using an Acuson Sequoia, Aspen, or 128 XP (Mountain
View, CA, USA) and GE Vivid 3 (Milwaukee, WI, USA)
ultrasound machine. Every patient underwent a com-
plete two-dimensional, M-mode, and Doppler echocar-
diography study. A tricuspid regurgitation systolic jet was
recorded from the parasternal or apical window with the
continuous-wave Doppler probe. Systolic right ventricu-
lar (or pulmonary artery) pressure was calculated using
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Fig. 2. Distribution of systolic pulmonary artery pressure (SPAP) ac-
cording to degree of 99mTc-MDP pulmonary uptake.
the modified Bernoulli equation given by: PAP = 4 × (tri-
cuspid systolic jet)2 + 10 mm Hg (estimated right atrial
pressure). PHT was defined as a systolic PAP ≥35 mm
Hg. Cardiac output was estimated from the left ventricu-
lar outflow tract velocity time integral × diameter.
99mTc-MDP pulmonary uptake
All patients underwent bone scintigraphy two hours
after intravenous injection of 740 MBq of 99mTc-MDP.
Whole skeleton planner scintigraphy was performed us-
ing a dual- or a single-head digital gamma camera. The
99mTc-MDP uptake in the lungs was evaluated for each
patient from the planar view of the chest. The degree of
lung uptake was determined by a nuclear medicine spe-
cialist, who was not aware of the patient’s clinical and
laboratory data. The uptake was graded according to the
following scale: 0 = no uptake, 1 = mild uptake, inten-
sity less than bone uptake, 2 = lung uptake similar to
bone uptake, 3 = lung uptake greater than bone uptake.
Grade 0–1 uptakes were considered as normal (Fig. 3A),
and grade 2–3 lung uptake of 99mTc-MDP (Fig. 3B) were
considered as elevated [11–13].
Data analysis
The incidence and the degree of PC were compared
between HD patients with and without PHT. The corre-
lation between the extent of PC, systolic PAP, and clini-
cal variables was evaluated using the two-tailed unpaired
Student t test for continuous data and chi-square analy-
sis for discrete data. Continuous data were expressed as
the mean values ± standard deviation (SD). Statistical
significance was set as P < 0.05.
RESULTS
Demographic and clinical data of the 49 HD patients
studied are presented in Table 1. There were 36 men
and 13 women with a mean age of 61.7 ± 13.2 years
(range 29 to 82 years). Mean duration of HD was 38.2 ±
43.7 months (range 7 to 234). The three most com-
mon etiologies of renal failure were diabetes mellitus
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Fig. 3. Grade 3 lung uptake of 99mTc-MDP. (A) Planar bone scintig-
raphy (anterior view-left, posterior view-right) of a 42-year-old woman
with ESRD who had been receiving hemodialysis for the last eight years
demonstrates abnormal diffuse lung uptake of the tracer, more promi-
nent at the bases. Grade 0 lung uptake of 99mTc-MDP. (B) Planar bone
scintigraphy (anterior view-left, posterior view-right) of a 34-year-old
male with ESRD who had been receiving hemodialysis for the last six
years demonstrates normal distribution of the tracer with no evidence
for lung uptake.
(28.6%), arterial hypertension (22.4%), and glomeru-
lopathy (18.4%).
Pulmonary calcification
Increased lung uptake of 99mTc-MDP (grade 2–3) was
found in 20 (40.8%) patients. Seventeen patients had
Table 1. Data on 49 patients with ESRD on hemodialysis via surgical
A-V shunt
Age years
Mean age 61.7 ± 13.2
Range 29–82
Sex
Male 36 (73.5%)
Female 13 (26.5%)
M/F ratio 2.8
Etiology of renal failure
Diabetes mellitus 14 (28.6%)
Hypertension 11 (22.4%)
Glomerulonephritis 9 (18.4%)
Chronic pyelonephritis 5 (10.2%)
Nephrolithiasis 5 (10.2%)
Polycystic kidney 3 (5.1%)
Unknown 2 (4.1%)
Duration of dialysis months
Mean 38.2 ± 43.7
Range 7–234
Systolic PAPa values mm Hg
No. of patients with SPAPa >35 28 (57.1%)
Mean SPAPa 46 ± 11
Pulmonary calcification
Grade 0 and 1 normal uptake 30 (59.2%)
Grade 2–3 elevated uptake 19 (40.8%)
Equal to bone (grade 2) 17
More than bone (grade 3) 3
aPAP, pulmonary artery pressure.
Table 2. Distribution of systolic PAP among HD patients with
normal and elevated 99mTc-MDP pulmonary uptake
99mTc- MDP pulmonary uptake
0–1 2–3
SPAP <35 11 10
SPAP >34 18 10
grade 2 uptake (equal to the bone), and 3 had grade 3
(higher than the bone). Twenty-nine patients had normal
uptake (grade 0–1). Review of the chest x-ray films of all
the patients and computerized tomography of the chest
of 35 patients (including all patients with PHT who un-
derwent CT as a part of the work-up to disclose etiology
for the PHT) revealed diffuse PC in only one patient with
grade 2 lung uptake and elevated PAP.
Pulmonary artery pressure studies
Systolic PAP of 28 (57.1%) patients was elevated. Their
mean systolic PAP was 46 ± 11 (range 35 to 85). Twenty-
one patients had normal systolic PAP (Table 1).
Correlations between increased uptake and PHT
Data on the distribution of systolic PAP values accord-
ing to the degree of 99mTc-MDP lung uptake are pre-
sented in Figure 2 and Table 2. Note the proportion of
PHT (18/29 vs. 10/20, respectively; P = 0.842) and the
mean systolic PAP (37 ± 11 vs. 40 ± 15, respectively; P =
0.335) did not differ significantly between patients with
and without elevated 99mTc-MDP lung uptake.
The data of 20 patients with and 29 patients with-
out elevated 99mTc-MDP were compared (Table 3). Age
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Table 3. Clinical and laboratory data between patients with and
without elevated pulmonary 99mTc-MDP uptake
Normal uptake Elevated uptake P value
No. of patients 29 (59.2%) 20 (40.8%)
Gender
Males/females 22/7 14/6 0.898
SPAPa >35 mm Hg 18/29 10/20 0.842
(% of patients)
SPAPa values mm Hg
Mean 37 ± 11 40 ± 15 0.335
Range 20–65 20–85
Age years
Mean 62.4 ± 140 60.8 ± 12.2 0.567
Range 29–80 36–82
Cardiac output L/min
Mean 6.05 ± 1.1 5.75 ± .9 0.231
Range 4.8–8.4 3.6–8
Time interval monthsc
Mean 42.2 ± 53.5 32.4 ± 0.5 0.353
Range 17–234 7–84
Medications
Antihypertensive 24 17 0.878
therapy
Beta blockers 15 15 0.573
Vasodilators
Ca channel blockers 17 12 0.85
ACE inhibitors 9 6 0.807
Hemoglobin 10.9 ± 1.8 11.3 ± 1.3 0.311
(mean ± SD)
Hematocrit % 34.3 ± 5.8 32.4.2 ± 6.3 0.196
PTHb level ng/L
Mean value 343 ± 266 267 ± 165 0.179
Range 11–1313 50–602
Ca-P product mg/dL
Mean value 44.2 ± 11 46 ± 13 0.532
Range 29.25–76 25–71
aSPAP, systolic pulmonary artery pressure; bPTH, parathyroid hormone;
cfrom onset of HD therapy to detection of pulmonary hypertension.
and gender distribution were similar for both subgroups,
as well as comorbid conditions and medications used.
Both groups had elevated cardiac output that did not dif-
fer significantly (6.05 ± 1.1 vs. 5.75 ± 0.9, respectively;
P = 0.231). The mean duration of HD was nonsignifi-
cantly higher in the normal uptake group (42.2 ± 53.5 vs.
32.4 ± 20.5, respectively; P = 0.353). Both subgroups had
reduced hemoglobin and hematocrit values, but the dif-
ferences between these values did not reach statistical
significance.
DISCUSSION
Vascular involvement is one of the most striking forms
of extraosseous calcification in chronic renal failure [14–
16]. The aorta and the coronary arteries [17] are mainly
affected, but peripheral small vessels in the systemic and
the pulmonary circulation are also affected [5]. Affected
vessels become stiffer independent of age or hyperten-
sion. The impact of this phenomenon on the pulmonary
circulation has not been studied previously.
Autopsy studies of HD patients [5–7] have shown that
pulmonary vascular calcification occurs frequently. Of 15
patients studied [5], nine (66%) had evidence of vascu-
lar calcification; in its mild form, fine linear and granu-
lar deposits along the alveolar capillary wall were noted,
while the more severe cases had linear calcification of the
elastic laminae and muscle fibers that in some cases was
accompanied by loose intimal fibrosis with narrowing of
the vessel lumens. Another study of 56 HD patients [6]
found PC in 75% of the cases (severe −48.2%), and noted
that in general the vascular and the parenchymal changes
were parallel. Contrary to pathologic studies, PC is sel-
dom recognized clinically. This discrepancy is explained
by the relatively minor tissue reaction evoked by the small
size of deposited crystals.
Pulmonary hypertension is a new entity in HD patients
[7]. Its occurrence in patients with elevated cardiac output
suggests failure of the pulmonary vasculture to maintain
the A-V access–mediated elevated CO. Increased stiff-
ness of pulmonary vasculture due to vascular calcifica-
tion is a possible mechanism. This notion is supported by a
study [18] of two subgroups of a dog model of ESRD, one
with an intact parathyroid and the other parathyroidec-
tomized. This study showed increased PTH activity, lung
calcium content, and PAP values in the dogs with intact
parathyroid glands, thus suggesting a link between PC to
PHT through the parathyoid hormone.
In this study, PC expressed by lung uptake of 99mTc-
MDP bone scintigraphy was present in 40% of the pa-
tients, but was not correlated to PAP values. Fifty percent
of the patients with increased uptake had no PHT, while
62% of the patients with normal uptake had PHT. This
study does not find a role for PC expressed by lung uptake
of 99mTc-MDP bone scintigraphy in the pathogenesis of
PHT in HD patients.
In other words, the high prevalence of lung uptake of
99mTc-MDP reflects scinigraphic findings without hemo-
dynamic significance. A possible explanation is that
the lung uptake of the tracer used reflects pulmonary
parenchymal rather than vascular calcification. Alter-
nately, it could reflect the presence of nonsignificant vas-
cular calcification. Two autopsy studies [5, 6] support the
latter notion.
As the marker used, 99mTc-MDP is taken up only where
calcium is actively deposited, and does not simply cor-
relate with its anatomic presence [12]; its yield for the
detection of vascular calcification is questionable. Others
have limited its use in the population of HD patients be-
cause it has a relatively low uptake by amorphous white-
lockite type mineral ([CaMg]3[PO4]2), the predominant
calcium salt in ESRD-associated metastatic calcification
[2].
99mTc-MDP bone scan is considered a sensitive but
not specific measure for the detection of PC. Of 23 HD
patients with normal chest radiograph, 14 (61%) had
increased 99mTc-MDP lung uptake [11]. Another study
demonstrated markedly increased 99mTc-MDP lung up-
take confirmed by histology in only 1 of 30 HD patients
[13]. Although elevated chest-to-spine ratio was found
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in 66% of the patients, it was considered inconclusive
for the presence of PC due to lack of histologic proof.
The present study shows similar data: 40% prevalence of
99mTc-MDP lung uptake without corresponding findings
in x-ray films or CT of the chest.
Because histologic lung studies are not always avail-
able, there is a need for noninvasive measures for the
presence and the extent of PC. The standard chest x-
ray is relatively insensitive for the detection of diffuse
PC. Conger [5] reported abnormal chest x-ray in only
1/15 HD patients with microscopic PC. High-resolution
CT of the chest occupying a mediastinal window with
or without densitometry measurements provides better
results; however, false-negatives may result from the
microscopic size of calcium salt crystals or from signal-
averaging from a relative large soft tissue component [8–
10]. Electron beam CT and spiral CT are highly sensitive
techniques for detecting coronary artery calcification,
and are being used with increasing frequency for screen-
ing asymptomatic individuals at risk for the development
of coronary artery disease [19]. MRI is relatively insen-
sitive for detecting PC because neither calcium nor air
in the lung typically transmits a signal, thereby failing to
produce a contrast [20].
Our previous observation [7] of reversibility of PHT
among HD patients who underwent successful kidney
transplantation, although their A-V access remained
patent, indicates a role for a humoral factor in this
syndrome. In a more recent study [21], we noted that
decreased NO production under basal and stimulatory
conditions in the population of patients with PHT con-
firms this observation. It appears that HD therapy is as-
sociated with reversible endothelial dysfunction.
Coexistence of PC and PHT in the population of ESRD
patients raises several points of interest. Pulmonary vas-
cular calcification and even arteriosclerosis have been de-
scribed in several conditions characterized by increased
vessel wall shear stress, such as increased pulmonary
blood flow and PHT caused by congenital left-to-right
shunt [22, 23]. The population of HD patients shares sim-
ilar hemodynamic features that might contribute further
to the development of PC.
CONCLUSION
Based on our observations, we conclude that an insub-
stantial number of ESRD patients receiving HD therapy
have increased lung uptake of 99mTc-MDP on bone scan,
not correlated to PAP values.
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